Plenty of innovation has bolstered that progress over the past few years. Nearly one year ago, Dexcom launched its next-generation G7 CGM. Last month, the company announced new integrations with automated insulin delivery systems from Tandem and Beta Bionics.
Now, the company can expect even more growth, thanks to its next major product launch.
Dexcom announced that it submitted its new sensor, Stelo, to the FDA for review. The company expects to launch Stelo, which is designed for people with type 2 diabetes who don’t use insulin, this coming summer.
“Our mission is to empower people to control health and this is the first step along that journey,” Sayer told Drug Delivery Business News. We’ll always be very active in the insulin-using world. That is our core business. Those are our core customers and, really, the people that have gone with us this on this journey. We’re never going to abandon that.
“We’ll continue to advance and enhance our technologies here but we just think glucose can be such a vital sign for other people wanting to control their health.”